Frontlight ResearchEarly access
CompletedPhase 2
A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Key facts
- Who runs it
- VivaVision Biotech, Inc
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 89 people enrolled
- Started
- 27 Nov 2023
- Ended
- 29 Dec 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VVN461 Ophthalmic Solution 1.0%
- VVN461 Ophthalmic Solution 0.5%
- Prednisolone acetate
- Record updated
- 27 January 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age 18-70 years at the time providing signed informed consent
- At least 1 eye diagnosed with noninfectious anterior uveitis at the time of screening
- Willing and able to comply with study requirements and visit schedule
Who cannot take part
- Diagnosis of intermediate uveitis, posterior uveitis or panuveitis in either eye at the time of screening
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis
The 3 groups in the trial
- VVN461, 1.0%Treatment being tested
VVN461 Ophthalmic Solution, 1.0%
Treatment: VVN461 Ophthalmic Solution 1.0%
- VVN461, 0.5%Treatment being tested
VVN461 Ophthalmic Solution, 0.5%
Treatment: VVN461 Ophthalmic Solution 0.5%
- Prednisolone acetate, 1%Placebo, for comparison
Prednisolone acetate Ophthalmic Solution, 1%
Treatment: Prednisolone acetate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Double-masked, Active-controlled, Multi-center Phase 2 Clinical Study Evaluating the Efficacy and Safety of 0.5% and 1.0% VVN461 Ophthalmic Solution in Patients With Noninfectious Anterior Uveitis
- Record updated
- 27 January 2025